Morgan Stanley downgraded Grifols (GRFS) to Equal Weight from Overweight with a price target of EUR 11, down from EUR 14. The firm cites uncertainties around the company’s revenue growth amid the albumin and alpha-1 slowdown. Decaling albumin sales in China and the slowdown of alpha-1 are leading Grifols to limit volume growth in 2026 to protect margins, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Grifols Doubles 2025 Profit and Secures Key Plasma and Fibrinogen Approvals
- Grifols Swings to Profit as Board Signs Off 2025 Annual Accounts
- Grifols reports Q4 adjusted EBITDA EUR 467M, consensus EUR 469.7M
- Grifols sees 2026 adjusted EBITDA growth 5%-9%
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?